Trastuzumab Deruxtecan Gets Priority Review for Previously Treated HER2-Mutant Metastatic NSCLC
The FDA has granted Priority Review to fam-trastuzumab deruxtecan-nxki to treat adults with previously treated HER2-mutant metastatic NSCLC.
The FDA has granted Priority Review to fam-trastuzumab deruxtecan-nxki to treat adults with previously treated HER2-mutant metastatic NSCLC.
Tiragolumab is a monoclonal antibody that works by binding to TIGIT, a protein receptor on immune cells, and suppresses the immune response to cancer.
A study sought to determine whether overweight/obesity is a factor in the development of thrombosis in cancer patients with peripherally inserted central catheters.
A team of investigators studied an artificial intelligence model’s accuracy in classification of images obtained from rapid on-site examination of EBUS-TBNA smears in the bronchoscopy suite.
Investigators compared the clinical course, risk factors, and outcomes of cancer patients with COVID-19 with non-cancer patients with COVID-19.